Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$3.94M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$4.47M

FY 2025 · Annual

-37.9% YoY

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$9.0M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$316.0K
+ Other Non-Cash$4.7M
= Operating Cash Flow-$3.9M
- Capex$0
= Free Cash Flow-$3.9M

Analysis

FY2025 free cash flow is -$3.9M. FCF conversion is 43.9% of net income. Operating cash flow was -$3.9M, with capex of $0. The largest bridge item is Other Non-Cash at $4.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportSep 14, 2026
8-KCurrent reportSep 1, 2026
10-QQuarterly reportAug 13, 2026
ARSARS filingJul 28, 2026

Does PLYX generate free cash flow?

Polaryx Therapeutics, Inc. Common Stock (PLYX) generated -$3.94M of free cash flow in fiscal 2025.

How much operating cash flow does PLYX produce?

Operating cash flow was -$3.94M, before capital expenditures of $0.00.